Page last updated: 2024-12-11
clathrodin
Description
Research Excerpts
Clinical Trials
Roles
Classes
Pathways
Study Profile
Bioassays
Related Drugs
Related Conditions
Protein Interactions
Research Growth
Market Indicators
Description
clathrodin: structure given in first source; isolated from marine sponges of the genus Agelas [Medical Subject Headings (MeSH), National Library of Medicine, extracted Dec-2023]
Cross-References
| ID Source | ID |
|---|---|
| PubMed CID | 5388709 |
| CHEMBL ID | 465679 |
| SCHEMBL ID | 13036741 |
| MeSH ID | M0207440 |
Synonyms (16)
| Synonym |
|---|
| nsc-638206 |
| nsc638206 |
| n-[(e)-3-(2-imino-1,3-dihydroimidazol-4-yl)allyl]-1h-pyrrole-2-carboxamide |
| n-(3-(2-imino-2,3-dihydro-1h-imidazol-4-yl)-2-propenyl)-1h-pyrrole-2-carboxamide |
| clathrodin |
| CHEMBL465679 |
| n-[(e)-3-(2-amino-1h-imidazol-5-yl)prop-2-enyl]-1h-pyrrole-2-carboxamide |
| 135383-64-1 |
| 1h-pyrrole-2-carboxamide, n-(3-(2-amino-1h-imidazol-4-yl)-2-propenyl)-, (e)- |
| SCHEMBL13036741 |
| bdbm50456973 |
| CS-0065478 |
| n-[(2e)-3-(2-amino-1h-imidazol-5-yl)prop-2-en-1-yl]-1h-pyrrole-2-carboxamide |
| EN300-7456509 |
| HY-116436 |
| AKOS040748152 |
Research Excerpts
Overview
Clathrodin is a marine alkaloid. It is believed to be a modulator of voltage-gated sodium channels.
| Excerpt | Reference | Relevance |
|---|---|---|
| "Clathrodin is a marine alkaloid and believed to be a modulator of voltage-gated sodium (Na(V)) channels. " | ( Action of clathrodin and analogues on voltage-gated sodium channels. Chan-Porter, F; Ilaš, J; Kikelj, D; Kirby, R; Madge, D; Peigneur, S; Tytgat, J; Zidar, N; Zula, A, 2014) | 2.25 |
[information is derived through text-mining from research data collected from National Library of Medicine (NLM), extracted Dec-2023]
Protein Targets (6)
Inhibition Measurements
| Protein | Taxonomy | Measurement | Average | Min (ref.) | Avg (ref.) | Max (ref.) | Bioassay(s) |
|---|---|---|---|---|---|---|---|
| Potassium voltage-gated channel subfamily A member 6 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 3.7000 | 4.3000 | 4.9000 | AID1379140 |
| Potassium voltage-gated channel subfamily A member 3 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0020 | 3.1969 | 8.0000 | AID1379137 |
| Potassium voltage-gated channel subfamily A member 4 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 2.1000 | 3.7000 | 5.3000 | AID1379138 |
| Potassium voltage-gated channel subfamily A member 5 | Homo sapiens (human) | IC50 (µMol) | 30.0000 | 0.0300 | 3.7300 | 9.0000 | AID1379139 |
| [prepared from compound, protein, and bioassay information from National Library of Medicine (NLM), extracted Dec-2023] | |||||||
Biological Processes (50)
Molecular Functions (18)
Ceullar Components (38)
Bioassays (13)
| Assay ID | Title | Year | Journal | Article |
|---|---|---|---|---|
| AID1379150 | Inhibition of rat Kv10.1 expressed in Xenopus laevis oocytes at 1 uM at -90 mV holding potential by two-electrode voltage clamp assay relative to control | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
| AID1379149 | Inhibition of rat Kv1.6 expressed in Xenopus laevis oocytes at 1 uM at -90 mV holding potential by two-electrode voltage clamp assay relative to control | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
| AID1379146 | Inhibition of rat Kv1.3 expressed in Xenopus laevis oocytes at 1 uM at -90 mV holding potential by two-electrode voltage clamp assay relative to control | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
| AID1379139 | Inhibition of human Kv1.5 expressed in CHO cells at -80 mV holding potential by whole cell automated patch clamp method | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
| AID1379144 | Inhibition of rat Kv1.1 expressed in Xenopus laevis oocytes at 1 uM at -90 mV holding potential by two-electrode voltage clamp assay relative to control | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
| AID1379140 | Inhibition of human Kv1.6 expressed in CHO cells at -80 mV holding potential by whole cell automated patch clamp method | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
| AID1379145 | Inhibition of rat Kv1.2 expressed in Xenopus laevis oocytes at 1 uM at -90 mV holding potential by two-electrode voltage clamp assay relative to control | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
| AID1379148 | Inhibition of rat Kv1.5 expressed in Xenopus laevis oocytes at 1 uM at -90 mV holding potential by two-electrode voltage clamp assay relative to control | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
| AID1379136 | Inhibition of human Kv1.2 expressed in CHO cells at -80 mV holding potential by whole cell automated patch clamp method | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
| AID1379138 | Inhibition of human Kv1.4 expressed in CHO cells at -80 mV holding potential by whole cell automated patch clamp method | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
| AID1379147 | Inhibition of rat Kv1.4 expressed in Xenopus laevis oocytes at 1 uM at -90 mV holding potential by two-electrode voltage clamp assay relative to control | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
| AID1379135 | Inhibition of human Kv1.1 expressed in CHO cells at -80 mV holding potential by whole cell automated patch clamp method | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
| AID1379137 | Inhibition of human Kv1.3 expressed in CHO cells at -80 mV holding potential by whole cell automated patch clamp method | 2017 | European journal of medicinal chemistry, Oct-20, Volume: 139 | Clathrodin, hymenidin and oroidin, and their synthetic analogues as inhibitors of the voltage-gated potassium channels. |
| [information is prepared from bioassay data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||||
Research
Studies (10)
| Timeframe | Studies, This Drug (%) | All Drugs % |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 2 (20.00) | 18.2507 |
| 2000's | 0 (0.00) | 29.6817 |
| 2010's | 8 (80.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||
Market Indicators
Research Demand Index: 11.92
According to the monthly volume, diversity, and competition of internet searches for this compound, as well the volume and growth of publications, there is estimated to be weak demand-to-supply ratio for research on this compound.
| This Compound (11.92) All Compounds (24.57) |
Study Types
| Publication Type | This drug (%) | All Drugs (%) |
|---|---|---|
| Trials | 0 (0.00%) | 5.53% |
| Reviews | 0 (0.00%) | 6.00% |
| Case Studies | 0 (0.00%) | 4.05% |
| Observational | 0 (0.00%) | 0.25% |
| Other | 10 (100.00%) | 84.16% |
| [information is prepared from research data collected from National Library of Medicine (NLM), extracted Dec-2023] | ||